Show simple item record

dc.contributor.authorLarsen, Simone B
dc.contributor.authorHanss, Zoe
dc.contributor.authorCruciani, Gerald
dc.contributor.authorMassart, Francois
dc.contributor.authorBarbuti, Peter A
dc.contributor.authorMellick, George
dc.contributor.authorKruger, Rejko
dc.date.accessioned2020-08-10T02:24:16Z
dc.date.available2020-08-10T02:24:16Z
dc.date.issued2020
dc.identifier.issn1873-5061
dc.identifier.doi10.1016/j.scr.2020.101776
dc.identifier.urihttp://hdl.handle.net/10072/396353
dc.description.abstractFibroblasts were obtained from a 76 year-old man diagnosed with Parkinson's disease (PD). The disease is caused by a heterozygous p.D620N mutation in VPS35. Induced pluripotent stem cells (iPSCs) were generated using the CytoTune™-iPS 2.0 Sendai Reprogramming Kit (Thermo Fisher Scientific). The presence of the c.1858G > A base exchange in exon 15 of VPS35 was confirmed by Sanger sequencing. The iPSCs are free of genomically integrated reprogramming genes, express pluripotency markers, display in vitro differentiation potential to the three germ layers and have karyotypic integrity. Our iPSC line will be useful for studying the impact of the p.D620N mutation in VPS35 in vitro.
dc.description.peerreviewedYes
dc.description.sponsorshipParkinsons Queensland Incorporation
dc.description.sponsorshipAegium Foundation
dc.languageEnglish
dc.publisherElsevier
dc.relation.ispartofpagefrom101776
dc.relation.ispartofjournalStem Cell Research
dc.relation.ispartofvolume45
dc.relation.urihttp://purl.org/au-research/grants/NHMRC/APP1084560
dc.relation.grantIDAPP1084560
dc.relation.fundersNHMRC
dc.subject.fieldofresearchBiological Sciences
dc.subject.fieldofresearchMedical and Health Sciences
dc.subject.fieldofresearchcode06
dc.subject.fieldofresearchcode11
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsCell & Tissue Engineering
dc.subject.keywordsBiotechnology & Applied Microbiology
dc.subject.keywordsCell Biology
dc.titleInduced pluripotent stem cell line (LCSBi001-A) derived from a patient with Parkinson's disease carrying the p.D620N mutation in VPS35
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationLarsen, SB; Hanss, Z; Cruciani, G; Massart, F; Barbuti, PA; Mellick, G; Kruger, R, Induced pluripotent stem cell line (LCSBi001-A) derived from a patient with Parkinson's disease carrying the p.D620N mutation in VPS35, Stem Cell Research, 2020, 45, pp. 101776
dcterms.dateAccepted2020-03-17
dcterms.licensehttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.date.updated2020-08-10T02:18:58Z
dc.description.versionPublished
gro.rights.copyright© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, providing that the work is properly cited.
gro.hasfulltextFull Text
gro.griffith.authorMellick, George


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record